Press Releases
June 03, 2025
​
SEITO Biologics AG raises over CHF 2.8 million to develop its
T regulatory cell engagers
​​
​
​
​
Küsnacht, Switzerland – SEITO Biologics AG ("SEITO"), a preclinical-stage biotechnology company developing novel immunotherapies for autoimmune and chronic-inflammatory diseases, announced today that it has raised over CHF 2.8 million financed by private investors and the Lichtsteiner Foundation.
"This funding will significantly contribute to the development of our proprietary T regulatory cell engagers for the treatment of patients with autoimmune and chronic-inflammatory diseases", said Onur Boyman, M.D., Chief Executive Officer of SEITO. These immunotherapies are high-precision off-the-shelf immunomodulatory treatments targeting immune-mediated disorders causing autoimmunity, inflammation, and even transplant rejection. SEITO's innovation harnesses the body's regulatory T cells to correct the underlying immunological problem of immune-mediated disorders, however, without the need of immunosuppression. "SEITO's T regulatory cell engagers have shown very promising results in several preclinical animal models", commented Ufuk Karakus, Ph.D., Chief Scientific Officer of SEITO.
​
​
About SEITO Biologics AG
SEITO is a spin-off from the University of Zurich. The company combines nearly two decades of pioneering research in immunology and development of novel immunotherapies with expertise in entrepreneurship. Its vision is to become a biotechnology leader in developing treatments for immune-mediated disorders. For more information, visit seitobio.ch or follow us on LinkedIn.
​
​
About Lichtsteiner Foundation
The Lichtsteiner Foundation invests in early-stage startups in the fields of medical technology, life science, mental health, public health, and wellbeing, to help pioneers bring their inventions to life. The foundation focuses on impact investing by providing funding in the form of equity. Check the website for more information: https://lichtsteinerfoundation.org/ or follow on LinkedIn.
Contact
Onur Boyman, CEO
SEITO Biologics AG
info@seitobio.ch
​
​
Sabina Sperisen, CEO
Lichtsteiner Foundation
info@lichtsteinerfoundation.org
​​
​
​